The use of mitoxantrone in the treatment of patients with multiple sclerosis: report update
Costa V, McGregor M, Brophy J
Record ID 32006000828
French
Authors' objectives:
The objective of this report is to review new evidence on the clinical and safety aspects of mitoxantrone treatment in multiple sclerosis (MS) patients since the original Technology Assessment Unit (TAU) report of December 2002.
Authors' recommendations:
Since the last report no new evidence indicating more substantial or more permanent benefit of mitoxantrone treatment in a general MS population has been identified.
Further evidence of cardiotoxicity even at relatively low doses has been identified. There are also new reports suggesting increased risk of leukemia.
Three recent case studies report excellent results of mitoxantrone induction treatment in patients with highly aggressive forms of MS but suffer from a lack of any comparator group.
For these reasons the present indications for use of mitoxantrone in MS should be reconsidered.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.mcgill.ca/files/tau/mitoxantrone_report_May23FINAL.pdf
Year Published:
2006
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Costs and Cost Analysis
- Mitoxantrone
- Multiple Sclerosis
Contact
Organisation Name:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
Contact Address:
Technology Assessment Unit of the MUHC, 536-5100 Boul. Maisonneuve O, Montreal, H4A 3T2
Contact Name:
eva.suarthana@mcgill.ca
Contact Email:
nisha.almeida@muhc.mcgill.ca
Copyright:
Technology Assessment Unit of the McGill University Health Centre (MUHC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.